Akebia Therapeutics (AKBA) said late Wednesday it priced its underwritten public offering of 25 million shares at $2 per share to raise about $50 million in gross proceeds.
The company said it also granted underwriters a 30-day option to purchase up to 3.8 million additional shares at the offering price.
The offering is expected to close on March 21.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments